CD123 targeted CAR-NK cells vs Tagraxofusp

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: CD123 · full Acute Myeloid Leukemia pipeline

CD123 targeted CAR-NK cells

Developed by Chongqing Precision Biotech Co., Ltd

Phase 1/2 in Acute Myeloid Leukemiacell therapy (CAR-NK)
Weak signal

NCT06006403 · Phase 1/2 · completed

This was a non-randomized, open-label study with no comparator and only five participants. Its primary outcomes included safety and objective response rate, but results are not posted, so whether the primary outcomes were met cannot be determined.

Next expected readout: June 2027 · NCT06690827 (registry estimate)

No aligned efficacy figure on record for this race.

Tagraxofusp

Marketed by Stemline Therapeutics, Inc.

Phase 2 in Acute Myeloid Leukemiafusion protein
Weak signal

NCT02113982 · Phase 1/2 · completed

The study was non-randomized, open-label, single-arm, and had no comparator; although complete response is a clinical disease outcome, the main efficacy cohort included only 13 patients. Its reported response rate therefore provides limited controlled evidence for tagraxofusp, and no formal between-treatment primary endpoint comparison was applicable.

Next expected readout: April 2027 · NCT06498973 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCD123 targeted CAR-NK cellsTagraxofusp
OS, median—Not reported—Not reported
Complete remission—Not reported—Not reported
Event-free survival, median—Not reported—Not reported
Duration of response, median—Not reported—Not reported

OS, median

CD123 targeted CAR-NK cells
—Not reported
Tagraxofusp
—Not reported

Complete remission

CD123 targeted CAR-NK cells
—Not reported
Tagraxofusp
—Not reported

Event-free survival, median

CD123 targeted CAR-NK cells
—Not reported
Tagraxofusp
—Not reported

Duration of response, median

CD123 targeted CAR-NK cells
—Not reported
Tagraxofusp
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

CD123 targeted CAR-NK cells: no structured comparison results are available for Acute Myeloid Leukemia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. CD123 targeted CAR-NK cells: 0 of 4 rows · Tagraxofusp: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricTagraxofusp
Dropout rate
n/a: no completion milestone16 µg/kg/daya
NCT02113982 · Phase 1/2
show 13 more results
—16 µg/kg/day
NCT02113982 · Phase 1/2
n/a: no completion milestone12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
n/a: no completion milestone12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
n/a: no completion milestone12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
n/a: no completion milestone9 µg/kg/day
NCT02113982 · Phase 1/2
n/a: no completion milestone7 µg/kg/day
NCT02113982 · Phase 1/2
n/a: no completion milestone7 µg/kg/day
NCT02113982 · Phase 1/2
Discontinued due to AEs
66.7%16 µg/kg/daya
NCT02113982 · Phase 1/2
show 13 more results
—16 µg/kg/day
NCT02113982 · Phase 1/2
0%12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
0%12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
100%12 µg/kg/day
NCT02113982 · Phase 1/2
—12 µg/kg/day
NCT02113982 · Phase 1/2
0%9 µg/kg/day
NCT02113982 · Phase 1/2
33.3%7 µg/kg/day
NCT02113982 · Phase 1/2
0%7 µg/kg/day
NCT02113982 · Phase 1/2
Serious AEs
100%16 µg/kg/daya
NCT02113982 · Phase 1/2
show 13 more results
100%16 µg/kg/day
NCT02113982 · Phase 1/2
33.3%12 µg/kg/day
NCT02113982 · Phase 1/2
53.8%12 µg/kg/day
NCT02113982 · Phase 1/2
30.8%12 µg/kg/day
NCT02113982 · Phase 1/2
54.1%12 µg/kg/day
NCT02113982 · Phase 1/2
100%12 µg/kg/day
NCT02113982 · Phase 1/2
60%12 µg/kg/day
NCT02113982 · Phase 1/2
71.4%12 µg/kg/day
NCT02113982 · Phase 1/2
100%12 µg/kg/day
NCT02113982 · Phase 1/2
55.9%12 µg/kg/day
NCT02113982 · Phase 1/2
100%9 µg/kg/day
NCT02113982 · Phase 1/2
33.3%7 µg/kg/day
NCT02113982 · Phase 1/2
66.7%7 µg/kg/day
NCT02113982 · Phase 1/2
Most frequent reported AEs
16 µg/kg/daya
aspartate aminotransferase increased 83.3%
anaemia 66.7%
hyperglycaemia 66.7%
NCT02113982 · Phase 1/2
show 13 more results
16 µg/kg/day
alanine aminotransferase increased 100%
arthralgia 100%
aspartate aminotransferase increased 100%
NCT02113982 · Phase 1/2
12 µg/kg/day
alanine aminotransferase increased 66.7%
aspartate aminotransferase increased 66.7%
hyperglycaemia 66.7%
NCT02113982 · Phase 1/2
12 µg/kg/day
alanine aminotransferase increased 61.5%
nausea 61.5%
aspartate aminotransferase increased 53.8%
NCT02113982 · Phase 1/2
12 µg/kg/day
alanine aminotransferase increased 76.9%
aspartate aminotransferase increased 69.2%
fatigue 53.8%
NCT02113982 · Phase 1/2
12 µg/kg/day
alanine aminotransferase increased 64.9%
aspartate aminotransferase increased 59.5%
pyrexia 48.6%
NCT02113982 · Phase 1/2
12 µg/kg/day
alanine aminotransferase increased 100%
fatigue 100%
hyperglycaemia 100%
NCT02113982 · Phase 1/2
12 µg/kg/day
hypoalbuminaemia 80%
oedema peripheral 60%
pyrexia 60%
NCT02113982 · Phase 1/2
12 µg/kg/day
oedema peripheral 71.4%
alanine aminotransferase increased 42.9%
aspartate aminotransferase increased 42.9%
NCT02113982 · Phase 1/2
12 µg/kg/day
aspartate aminotransferase increased 100%
decreased appetite 100%
fatigue 100%
NCT02113982 · Phase 1/2
12 µg/kg/day
aspartate aminotransferase increased 64.7%
hypoalbuminaemia 61.8%
alanine aminotransferase increased 58.8%
NCT02113982 · Phase 1/2
9 µg/kg/day
alanine aminotransferase increased 100%
fatigue 100%
hyperglycaemia 100%
NCT02113982 · Phase 1/2
7 µg/kg/day
aspartate aminotransferase increased 100%
hypoalbuminaemia 100%
hypocalcaemia 100%
NCT02113982 · Phase 1/2
7 µg/kg/day
alanine aminotransferase increased 100%
decreased appetite 100%
dizziness 100%
NCT02113982 · Phase 1/2

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CD123 targeted CAR-NK cells's landscape · Tagraxofusp's landscape